<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290611</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-20-02</org_study_id>
    <nct_id>NCT04290611</nct_id>
  </id_info>
  <brief_title>a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY</brief_title>
  <acronym>VENDY</acronym>
  <official_title>Monitoring the Neurological Toxicity of Enzalumatide Through VigiBase, a Pharmacovigilance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enzalutamide may lead to various adverse reactions. This study investigates reports of
      different neurological toxicities in the World Health Organization's (WHO) global database of
      individual safety case reports (VigiBase).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enzalutamide are responsible of a wide range of side effects.The investigators use VigiBase,
      the World Health Organization (WHO) database of individual safety case reports, to identify
      cases of adverse drug reactions following treatment with enzalutamide
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with neurological adverse events with significant over-reporting enzalutamide</measure>
    <time_frame>Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020</time_frame>
    <description>Identification and report of neurological toxiciy of enzalutamdie</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Neuropathy</condition>
  <condition>Epilepsy</condition>
  <condition>Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Enzalutamide drug-induced toxicity</arm_group_label>
    <description>Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide for the treatment of prostate cancer or other solid tumors</description>
    <arm_group_label>Enzalutamide drug-induced toxicity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with enzalutamide for prostate cancer or other solid tumors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the World Health Organization (WHO) database of individual safety
             case reports to 01/01/2020 Adverse events reported were including any MedDRA terms
             Patients treated with enzalutamide reported in the WHO database.

        Exclusion Criteria:

          -  Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug-induced neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

